RE: New strain...17 Aug 2020 19:15
Evening Woodstock, I only know as much as anyone else, RM said it was difficult filling trial as numbers in the community waned. I remember he mentioned they probably wouldn’t fill it until the 2nd wave hit. I know we are averaging just over a thousand a day now for the last week, so I would imagine they are picking up a few. The trial parameters also stated that the trial could be ended early due to lack of numbers so I don’t see it as impossible that If they get to say 60-70 they may be given permission to analyse the data, like the COPD readout. As an aside it took my interest that a company called SERES who were running a phase III trial on C-diff infection were being considered for FDA approval but that the FDA normally would work on a minimum number of 300 patients to asses efficacy and safety. So, if you take the COVID trial number so far, the COPD trial and the older Asthma data along with home trial numbers They must be over that limit or very close to it. Interesting thought.